Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?

Area of Science:

• Geriatric Medicine
• Pharmacology
• Muscle Physiology

Background:

• Osteoporosis and sarcopenia are common geriatric syndromes, frequently occurring together as osteosarcopenia.
• Current treatments for osteosarcopenia primarily target osteoporosis, lacking specific FDA-approved therapies for sarcopenia.
• Osteoporosis drug selection criteria do not typically account for co-existing sarcopenia.

Purpose of the Study:

• To review the effects of FDA-approved osteoporosis drugs on muscle quality, mass, and function.
• To highlight the potential impact of osteoporosis pharmacotherapy on muscle tissue.
• To inform future treatment strategies for osteosarcopenia.

Main Methods:

• Literature review of studies and clinical trials.
• Analysis of pharmacological effects of osteoporosis medications on muscle.
• Synthesis of current knowledge on drug interactions with muscle tissue.

Main Results:

• Osteoporosis drugs can exert positive or negative effects on muscle tissue.
• Existing osteoporosis treatments may influence sarcopenia progression.
• No specific osteoporosis drugs are approved for sarcopenia treatment.

Conclusions:

• Considering sarcopenia's impact is crucial when selecting osteoporosis treatments.
• Understanding drug effects on muscle can guide simultaneous management of bone and muscle loss.
• Further research may lead to therapies addressing both conditions concurrently.